Early bactericidal activity trial of nitazoxanide for pulmonary tuberculosis.

Clicks: 339
ID: 100423
2020
Article Quality & Performance Metrics
Overall Quality
Not rated
Combines reader engagement with the AI quality analysis. This article has not been analysed, so there is no overall score — reader engagement is measured and shown alongside.
AI Quality Assessment
Not analyzed
Readership in this journal
Emerging

Ranked #43 of 105 articles by views in Antimicrobial agents and chemotherapy

Most read Least read

Bar heights use a square-root scale.

Mint this article as an NFT
Not yet minted

Create a permanent, verifiable on-chain record of this article on the Scimatic Network. The NFT is held in your Journament account, and you can withdraw it to your own wallet at any time.

5 SUSD one-off · no wallet required
Sign in to mint
Abstract
SettingThis study was conducted in treatment-naïve adults with drug-susceptible pulmonary tuberculosis in Port-au-Prince, Haiti.ObjectiveTo assess the safety, bactericidal activity and pharmacokinetics of nitazoxanide (NTZ).DesignThis was a prospective phase II clinical trial in 30 adults with pulmonary tuberculosis. Twenty participants received NTZ 1 gram orally twice daily for 14 days. A control group of ten participants received standard therapy over 14 days. The primary outcome was the change in time to culture positivity in an automated liquid culture system.ResultsThe most common adverse events seen in the NTZ group were gastrointestinal complaints and headache. The mean change in TTP in sputum over 14 days in the NTZ group was 3.2 hours ± 22.6 and was not statistically significant (p=0.56). The mean change in TTP in the standard therapy group was significantly increased, at 134 hours ± 45.2 (p<0.0001). The mean NTZ minimum inhibitory concentration for isolates was 12.3 μg/mL; the mean NTZ plasma C was 10.2 μg/mL. Negligible NTZ levels were measured in sputum.ConclusionAt the doses used, NTZ did not show bactericidal activity against Plasma concentrations of NTZ were below the MIC and its negligible accumulation in pulmonary sites may explain the lack of bactericidal activity.
Reference Key
walsh2020earlyantimicrobial Use this key to autocite in the manuscript while using SciMatic Manuscript Manager or Thesis Manager
Authors Walsh, K F;McAulay, K;Lee, M H;Vilbrun, S C;Mathurin, L;Francois, D Jean;Zimmerman, M;Kaya, F;Zhang, N;Saito, K;Ocheretina, O;Savic, R;Dartois, V;Johnson, W D;Pape, J W;Nathan, C;Fitzgerald, D W;
Journal Antimicrobial agents and chemotherapy
Year 2020
DOI
AAC.01956-19
URL
Keywords
implementation leadership characteristics champion quality improvement program

Citations

No citations found. To add a citation, contact the admin at info@scimatic.org

Comments

No comments yet. Be the first to comment on this article.